AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03207750 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevenar 13
Description: Three doses administered intramuscularly according to a 0, 2, 4 month schedule.
Study NCT03207750 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevenar 13
Description: Three doses administered intramuscularly according to a 0, 2, 4 month schedule.
Study NCT04492046 — intervention group
Intervention type: OTHER
Intervention: Manual Lymph Drainage
Description: Manual lymph drainage is an effective therapeutic method used in the conservative treatment of lipedema. The application was performed on both lower extremities for 45 minutes.
Study NCT04492046 — intervention group
Intervention type: OTHER
Intervention: Bandaging
Description: Multilayered compression bandaging techniques have an assisting role in the further reduction of the volume of the limb and enhance the continuous pump mechanism via the active involvement of muscle pumps. All patients received bandages following Manual lymph drainage application.
Study NCT02388321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: intranasal sub-dissociative dose ketamine for the treatment of moderate to severe pain in pediatric patients in the emergency department.
Study NCT02388321 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: intranasal fentanyl for the treatment of moderate to severe pain in pediatric patients in the emergency department.
Study NCT02462395 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: Sponge-electrodes (5 x 7 cm) will be postioned at Fz (anode) and over the spinous process of C7 (cathode). Stimulation intensity will be set to 2 mA.~A first group of CCH patients will have to apply the neurostimulation outside of an attack every day for 20 minutes during 4 weeks. A second group will use the tDCS device everyday for 8 weeks.~Adherence to the treatment will be evaluated by monitoring the time during which the device is switched on via an in-built software.
Study NCT01972061 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Foot stimulation
Description: Foot stimulation electrically activates the somatic afferent nerves in the foot using FDA-approved, commercially available transcutaneous electrical nerve stimulator (TENS) and skin surface electrodes attached to the foot.
Study NCT01972061 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Foot stimulation
Description: Foot stimulation electrically activates the somatic afferent nerves in the foot using FDA-approved, commercially available transcutaneous electrical nerve stimulator (TENS) and skin surface electrodes attached to the foot.
Study NCT00289341 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: vaccine vehicle only
Description: Subcutaneous injection of vaccine vehicle only (5% DMSO in normal saline), followed by cross-over to Arm 1 design.
Study NCT00289341 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC/LNCaP
Description: Subcutaneous injection of DC/LNCaP, DC/LNCaP-M1, DC/KLH
Study NCT04181034 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adolescent Family Life Program Positive Youth Development (PYD) program
Description: Home visiting program for pregnant and parenting teens with PYD component
Study NCT04181034 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Adolescent Family Life Program (AFLP)
Description: Home visiting program for pregnant and parenting teens
Study NCT01334697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human cardiotrophin-1
Description: Single dose intravenous administration
Study NCT01334697 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose intravenous administration
Study NCT02358486 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: 1. Acupuncture rationale 1a) Style of acupuncture: body acupuncture (in accordance with meridian theory)~2. Needling details 2a) Number of needle insertions per subject per session: 13 2b) Acupoints: Basic points - Large Intestine(LI)4, Stomach(ST)36, Liver(LR)3, Pericardium(PC)3, Spleen(SP)4, Stomach(ST)34, Conception Vessel(CV)12, 2c) Depth: 5 \~ 30mm 2d) Response sought: 'De qi' sensation; 2e) Needle stimulation: Manipulation 2f) Retention time: 15 minutes 2g) Needle type: 0.2 X 40 mm, sterilized stainless steel needle, Dongbang Inc., Korea
Study NCT02358486 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture
Description: The participants in sham acupuncture group are given sham acupuncture treatment at the same acupoints in the same times and method as acupuncture arm. The sham device would be a Streitberger device.
Study NCT02233712 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: G17DT
Study NCT02680600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefepime dosing
Description: Patients will received cefepime administered per standard-of-care as a 30 min intravenous infusion. Dosing will be based on local guidelines (the Sanford guide to antimicrobial therapy 2012-2013) using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine formula to estimate glomerular filtration rate (GFR).
Study NCT02680600 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Blood will be sampled immediately prior to dose administration (time = 0 at the start of the 30 min infusion), at 0.5, 1, 3, 5 hours post-start of infusion and just before the subsequent dose. From day two onwards, samples will be taken at the end of the infusion and just before the next dose. For the quantification of cefepime, a validated solid phase extraction-liquid chromatography electrospray-tandem mass spectrometry method will be used.
Study NCT02680600 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Urine sampling
Description: Timed urine collections were taken during one dosing interval (8 hours in a three times daily regimen) every day.
Study NCT02680600 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Determination of renal markers
Description: Creatinine (modified Jaffe method) and urea in serum will be determined using an Architect c16000 analyzer (Abbott, Chicago, IL, USA). Cystatin C will be determined using a particle-enhanced immunonephelometric assay (N Latex Cystatin C, Siemens Healthcare Diagnostics, Marburg, Germany) by use of a BN II nephelometer (Siemens Healthcare Diagnostics). This assay has a calibration traceable to the first certified reference material for cystatin C in human serum (ERM-DA471/IFCC). Kidney injury molecule-1 (KIM-1) in urine and uromodulin in serum will be determined using commercially available ELISA assays: Quantikine ELISA Human TIM-1/KIM-1/HAVCR (R\&D Systems, Minneapolis, MN, USA) and Uromodulin ELISA (Euroimmun, Luebeck, Germany), respectively.
Study NCT02680600 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Population pharmacokinetic modeling
Description: The cefepime concentration versus time data will be fitted using the FOCE-I estimation algorithm in NONMEM® (Version 7.3; GloboMax LLC, Hanover, MD, USA). R® (R foundation for statistical computing, Vienna, Austria) will be used to graphically assess the model's goodness-of-fit and to evaluate the model's predictive capabilities. As a measure of prediction error, the absolute prediction error (APE) will be used. In short, the measured cefepime concentrations for each individual i at time point j were compared against the population predicted cefepime concentrations, i.e. the predictions for each individual without taking into account the between-subject variability (PRED in NONMEM). The distribution of APEs will be summarized by the median and 90% percentile.
Study NCT02680600 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Covariate screening
Description: Renal function will be assessed by four serum based kidney markers (serum creatinine, cystatin C, urea and uromodulin) and two urinary markers (measured creatinine clearance (CrCl) and KIM-1, both on timed urine collections). Serum creatinine and cystatin C will also be used to calculate the eGFR based on CKD-EPI formulas.
Study NCT02680600 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Monte Carlo simulations
Description: Based on the final covariate model, a Monte Carlo-based simulation study will be performed to evaluate the Sanford dose recommendations for ICU patients.
Study NCT03152305 — intervention group
Intervention type: OTHER
Intervention: Intracranial pressure variations
Description: Self-measure of ICP will be performed outside and during menstrual migraine attacks.
Study NCT02632747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ramipril
Description: Ramipril will be taken once or twice daily
Study NCT03821428 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Needling of P6 and CV24 points
Study NCT03821428 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Application of placebo acupuncture needles to the areas, where the acupoints are situated
Study NCT01487330 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcatheter Aortic Valve Implantation (TAVI)
Description: Placement of the SJM TAVI aortic valve with a transfemoral delivery system.
Study NCT03223389 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: C-8 dietary oil
Description: Ingestion of 13.15 g C-8 dietary oil providing 0.0216 mol of triglycerides.
Study NCT03223389 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tricaprylin
Description: Ingestion of 10.17 g tricaprylin providing 0.0216 mol of triglycerides.
Study NCT03223389 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Olive oil
Description: Ingestion of 19 g olive oil providing 0.0216 mol of triglycerides.
Study NCT01286818 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ramucirumab (IMC-1121B)
Description: Ramucirumab (IMC-1121B): Intravenous (IV) infusions, 8 milligrams per kilogram (mg/kg) every 2 weeks
Study NCT01286818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: IV Infusion, 180 milligrams per square meter (mg/m²) every 2 weeks
Study NCT01286818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levofolinate
Description: IV infusion, 200 mg/m² every 2 weeks
Study NCT02282826 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Pharmaceutical form:solution Route of administration: intravenous
Study NCT02282826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GZ402668
Description: Pharmaceutical form:solution Route of administration: subcutaneous
Study NCT02450279 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: technetium-99m - Diethylenetriaminepentaacetic acid
Study NCT02450279 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vibrating-mesh nebulizer
Study NCT02450279 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Jet Nebulizer
Study NCT02450279 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Planar scintigraphy
Study NCT02450279 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative spirometry
Study NCT02282826 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Pharmaceutical form:solution Route of administration: subcutaneous
Study NCT02282826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acyclovir
Description: Pharmaceutical form:tablet Route of administration: oral
Study NCT02282826 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: acyclovir
Description: Pharmaceutical form:tablet Route of administration: oral
Study NCT04024280 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical exercise program
Description: Frequency: 3 weekly sessions. Intensity of aerobic training: reporting 12-17 in the Borg scale. Time of aerobic training: 10 minutes in the first and second weeks and then 2 added minutes at each 2 weeks. Type of aerobic training: walking and stepping. Intensity of resistance training: without load in the first week and, then, 15 submaximal repetitions. Time of resistance training: 30 minutes. Type of resistance training: using free weights; the lower body exercises will be squat, leg extension, leg curl and calf raise; the upper body exercises will be frontal and lateral arm raise, chest press, seated row and bicep curl.
Study NCT01286818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil (5-FU)
Description: 400 mg/m² bolus followed by a 2400 mg/m² continuous infusion, every 2 weeks
Study NCT01504438 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Salto-Talaris Total Ankle Replacement
Description: Salto-Talaris Total ankle replacement surgery
Study NCT01504438 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: STAR Total Ankle Replacement
Description: STAR Total Ankle Replacement
Study NCT02087800 — intervention group
Intervention type: BEHAVIORAL
Intervention: F phase lab session
Description: F phase sessions will occur three to seven days post the onset of menses. It will include blood draws, an acute stressor and completion of questionnaires.
Study NCT02087800 — intervention group
Intervention type: BEHAVIORAL
Intervention: L phase lab session
Description: L phase sessions will occur six to ten days prior to the onset of the next expected menses. It will include blood draws, an acute stressor and completion of questionnaires.
Study NCT03178734 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Foley Catheter vs Self-Contained Valved Catheter
Description: This study aims to compare UTI rates and patient satisfaction between an indwelling Foley catheter group (established SOC); and a relatively (FDA-approved) new valved addition to the Foley catheter which requires no drainage bag.
Study NCT03210142 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transvenous hypoglossal nerve stimulation
Description: Transvenous hypoglossal nerve stimulation to open upper airway.
Study NCT03541668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human urokinase
Description: Patients receive rhPro-UK 35mg,15mg of which is given as a bolus within 3 minutes followed by dlivery of the remaining 20 mg as a constant infusion over a period of 30 minutes.
Study NCT03541668 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alteplase
Description: Patients receive rt-PA in a dose of 0.9mg per kilogram of body weight(maximum,90 mg),10 percent of which was given as a blous followed by delivery of the remaining 90 percent as a constant infusion over a period of 60 minutes.
Study NCT02291172 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention JEP
Description: A blend of JASP-EMT using SGDs with parent training intervention with the addition of individualized DTT to teach receptive language, imitation, and joint attention when children lack these skills at entry.
Study NCT04113564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Study NCT01950195 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery (SRS)
Study NCT01950195 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Study NCT04653701 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: Chemoembolization with preloaded microparticles 100 micron and reflux control microcatheter
Description: We will perform chemoembolization technique in those patients (during 1 year) with indications for this treatment in relation with guidelines (early and intermediate hepatocellular carcinoma). Specific microcatheter and microparticles will be use (Mentioned above)
Study NCT02607293 — intervention group
Intervention type: DRUG
Intervention: Gonal-f®
Description: Recombinant human follicle stimulating hormone (r-FSH) will be administered subcutaneously (SC) for about 10 to 20 days along with the ART regimen as routinely practiced by Investigators and according to licensed summary of product characteristics (SmPC label) for the ovarian stimulation.
Study NCT03151226 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Capnography monitoring
Description: capnography and pulse oximetry will be initiated in the recovery room and worn for 12-24 hours post delivery
Study NCT04498936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir and Ledipasvir
Description: Evaluate the efficacy of Sofosbuvir/Ledipasvir in treatment of COVID-19
Study NCT04498936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitazoxanide
Description: Evaluate the efficacy of Nitazoxanide in treatment of COVID-19
Study NCT01491243 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intensive treatment with sodium bicarbonate
Description: i.v., sodium bicarbonate (3 ml/kg/h for 1 hour, then 1 ml/kg/h for 7 h) followed by i.v. saline for 48 h in case of abnormal NGAL findings
Study NCT01491243 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment with saline infusion
Description: i.v. 1 ml/kg/h saline infusion for 48 h in case of abnormal NGAL findings
Study NCT02598635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: Patients on peritoneal dialysis and 25-(OH) levels \<20 ng/mL will received one capsule of cholecalciferol (4800 U) once a day for 16 weeks.
Study NCT02598635 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: An oral placebo capsule matching Cholecalciferol in terms of appearance, smell and taste will be administered once a day for 16 weeks.
Study NCT00634413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Theophylline - ADC4022
Description: Inhaled theophylline (ADC4022) administered twice daily for 28 days
Study NCT00634413 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inhaled matching placebo administered twice daily for 28 days
Study NCT00634413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: Inhaled budesonide twice daily for 28 days
Study NCT00634413 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Budesonide
Description: Inhaled budesonide twice daily for 28 days
Study NCT01161511 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: XmAb5574
Description: Intravenous infusion of XmAb5574 administered weekly during two 28-day cycles with an additional dose being administered during the first week of Cycle 1. (Cycle 1 on Days 1, 4, 8, 15, 22; Cycle 2 on Days 1, 8, 15, 22)
Study NCT04305132 — intervention group
Intervention type: DEVICE
Intervention: Electroconvulsive therapy
Description: Thymatron System IV electroconvulsive therapy device
Study NCT04588701 — intervention group
Intervention type: PROCEDURE
Intervention: surgical procedures commonly done for anal fistula
Description: Surgical procedures performed, including fistulotomy; fistulotomy with sphincter repair; seton; advancement flap; fistula plug;
Study NCT02881398 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mHealth
Description: After randomization and at the time of the initial encounter, study subjects are assessed at the point-of-care with mHealth devices that measure symptoms, functional status, and for structural abnormalities. These devices include activity monitoring for an assessment of a 6-minute walk test, smartphone connected blood pressure, oxymetry and ECG for functional assessments, and structural assessments with handheld-echocardiography and point-of-care BNP. Treatment decisions for an intervention with percutaneous valvuloplasty or valve replacement were performed based on the aggregate of these mHealth findings. Confirmation of the severity of structural heart disease on transthoracic echocardiography was performed on all participants.
Study NCT02881398 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard-Care
Description: After randomization and at the time of the initial encounter, study subjects randomized to standard-care underwent a physical examination, 12-lead ECG, radiographic and laboratory tests as warranted and clinically required. Treatment decisions for percutaneous valvuloplasty or valve replacement were based on the aggregate of the standard-care findings. Confirmation of the severity of structural heart disease on transthoracic echocardiography was performed on all participants.
Study NCT01385137 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: omega-3 fatty acid
Description: Given orally
Study NCT01385137 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally
Study NCT03627117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verum
Description: Single vape of 0.25mL of CBD e-Liquid containing: 5% CBD (low-temperature extracted Cannabidiol from Cannabis sativa L., purity 99%), Glycerine (vegetable), Propylene glycol, water
Study NCT03627117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single vape of 0.25ml e-liquid La Baronne Jaune, BORDO2.
Study NCT02056431 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IVR Intervention Group
Description: Participants will receive 3 interactive voice response (IVR) calls (2nd, 4th, and 6th month post-treatment start date) to collect information on medication use, side effects, rating of side effects, and pain symptoms to be fed back to their physicians.
Study NCT03620760 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor 90 mg
Description: Ticagrelor (AZD6140) 90 mg twice daily dose
Study NCT00062244 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: oblimersen sodium
Description: Given IV
Study NCT01313559 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pasireotide
Description: Given IM
Study NCT01313559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide
Description: Given IM